Fig. 5From: First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysisPD, EORR and CI (No significant difference was observed in progressive disease (Fig. 5a) and the rate of curative intent metastasectomy(Fig. 5c). Only FIRE-3 trial reported that Cetuximab-based regimens were associated with a relatively higher EORR compared with bevacizumab-based regimens(Fig. 5b)Back to article page